TXMD TherapeuticsMD, Inc.

XNAS 1.80 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

TXMD $1.80 —
Key stats
$1.80
52-Week Range
$1.11 – $2.95
YTD
+9.09%
IV Rank (30D)
5.33
Straddle Price
$0.72
P/C Vol Ratio
0.09
Market Cap
$0.0B
Open
$1.77
Day Range
$1.76 – $1.81
Volume
6,387
Prev Close
$1.80
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY0.76
Cost of Equity (CAPM)8.74% (VRP-adj)
WACC8.88%
Volatility Risk Premium+242.7pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon12 years explicit + fade
Free Cash Flow (TTM)$0.0B
Return on Equity (TTM)-0.8%
Book / Price129.3% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)93.1%
Debt / Equity0.00
Quality Score4/6 — high quality (12y DCF)
SMA 50$2.07 (Market Anchor value)
SMA 20 / Bollinger Mid$1.96
Bollinger Width / SMA20861.1% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
57%
20-Day Fair Value
≈ by Nov 25, 2026
$1.80
α +0.0% rank 82%
conviction
2%
40-Day Fair Value
≈ by Dec 24, 2026
$1.83
α +1.6% rank 82%
conviction
53%
60-Day Fair Value
≈ by Jan 22, 2027
$1.83
α +1.8% rank 82%
conviction
57%
MethodImplied PriceWeightDetail
DCF $2.68 28%
DDM (Gordon) n/a 0%
Peer P/E $0.79 7% median 39.5× · 3 peers
Peer EV/EBITDA n/a 0% median 19.2× · 3 peers
Peer P/B $8.17 11% median 3.5× · 3 peers
Peer P/S $1.11 11% median 3.9× · 3 peers
Market Anchor (SMA50) $2.07 44% stability 78% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-27 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
1
List Date
2002-01-28
CIK
0000025743
Next Earnings
2026-11-11 (Pre-Market)
Headquarters
Boca Raton, FL
Homepage
https://www.therapeuticsmd.com

TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan33.06%-22.89%-15.68%-3.00%-31.21%30.91%-1.47%
Feb-13.14%-22.84%-6.59%6.19%-9.69%0.00%-7.68%
Mar-7.27%68.44%-23.63%-9.84%6.94%-9.82%4.14%
Apr-12.95%-46.57%-4.58%-18.97%26.53%2.00%-9.09%
May5.22%7.06%21.35%17.77%5.04%3.38%9.97%
Jun-4.80%0.10%-0.72%-27.15%5.45%4.25%-3.81%
Jul-17.36%-37.45%-2.87%2.34%-0.88%-7.09%-10.55%
Aug-21.29%16.45%-7.79%12.20%0.00%6.86%1.07%
Sep-6.70%-32.66%-20.11%-7.26%1.42%-6.45%-11.96%
Oct-1.23%3.09%-28.76%-5.49%12.26%-11.33%*-5.24%
Nov-34.74%-22.77%22.27%-8.33%47.83%--0.85%
Dec-22.28%27.92%-17.88%-37.23%7.24%---8.45%
Total-71.59%-71.33%-64.61%-62.61%66.58%6.88%-32.78%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $1.96
SMA 50: $2.07
SMA 200: $2.12
Current: $1.80
EMA 12: $1.90
EMA 26: $1.97
MACD: -0.0722 | Signal: -0.0152
BEARISH
ADX (14): 34.25
TREND
+DI: 6.55
−DI: 32.87

Momentum Oscillators

RSI (14): 28.62
OVERSOLD
Stoch %K: 20.85
Stoch %D: 29.96
Williams %R: -83.87

Volume & Volatility

BB Upper: $2.12
BB Lower: $1.79
NEUTRAL
OBV: 21,232,460
Vol SMA 20: 20,411
Vol ROC: -54.51%
ATR: $0.07
True Range: $0.05
HV 20: 25.4%
HV 30: 29.1%
HV 60: 33.7%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers:

  • Bullish momentum from MACD crossover
  • Neutral RSI reading
  • Low volatility compared to market

Primary Risks:

  • Lack of recent earnings or significant news driving price action
  • Consolidation near current levels may lead to sideways movement

Investment Thesis: TXMD has exhibited a neutral-to-bullish trend, with the MACD signaling a continued uptrend. However, the stock's low volatility and lack of recent catalysts suggest caution.

Recent News Sentiment Impact: The majority of recent news headlines are neutral or positive, with no significant events driving the stock's price action.

Technical Analysis

Trend Direction:

  • Short-term: NEUTRAL (No clear trend)
  • Medium-term: BULLISH (MACD crossover and rising ADX)
  • Long-term: NEUTRAL (SMA 200 and EMA 26 trending sideways)

Support/Resistance Levels:

  • Upper Bollinger Band: $2.32
  • Middle Line: $2.14
  • Lower Bollinger Band: $1.96

Momentum Signals:

  • RSI: 48.20 (Neutral)
  • MACD Signal: Bullish crossover
  • Bollinger Bands: Neutral signal

News & Sentiment Analysis

Recent Headlines Summary:

  • Positive news from the sexual wellness market and TherapeuticsMD's rating upgrade to Buy dominate the headlines.
  • Neutral sentiment prevails, with no significant events driving price action.

Sentiment Assessment: Positive (60%) > Neutral (30%) > Negative (10%)

Catalyst Identification: No imminent earnings or product launches; however, future announcements could impact the stock's performance.

Market Narrative: The market narrative is neutral to positive, with a focus on TherapeuticsMD's growth prospects in the sexual wellness industry.

Risk & Volatility Assessment

Beta Interpretation: Low risk (0.25 beta) compared to the market.

Volatility Regime: Historically low volatility (Stock Volatility: 0.76).

Options Market Signals:

  • IV Rank: Low (21.7%)
  • Current IV: 289.9% (High)
  • Expected Move: $10.32 (37 DTE), 7-DTE: $0.85
  • Volume Flow: Balanced call/put activity
  • Open Interest: No significant open interest in calls or puts

Market Context & Positioning

Sector Performance: TherapeuticsMD's sector, the sexual wellness industry, has been relatively strong.

Institutional Activity: No notable institutional buying or selling activity.

Correlation Analysis: Low correlation (0.04) with the market, indicating a potential safe-haven asset.

Relative Valuation: Positioned near the lower end of its trading range.

Key Levels & Action Items

Critical Price Levels:

  • Support: $2.14 (SMA 50), $1.96 (Lower Bollinger Band)
  • Resistance: $2.32 (Upper Bollinger Band)

Breakout/Breakdown Levels: No significant technical levels to monitor.

Time-Sensitive Catalysts: No imminent earnings or product launches; however, future announcements could impact the stock's performance.

Risk Management:

  • Stop-loss levels: Monitor support and resistance levels
  • Position sizing considerations: Use low volatility to your advantage by scaling in

Please note that this analysis is based on the provided data and should not be considered investment advice. It is essential to evaluate the report's findings, consider additional market information, and consult with a financial advisor before making any investment decisions.

Generated
Earnings History
15 of 17 under expected move
Avg Expected Move
89.23%
Avg Actual Move
4.74%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-03-02 Pre-Market 23.33% 0.35% 0.02x Within
2021-05-06 Pre-Market 28.23% 13.28% 0.47x Within
2021-08-04 Pre-Market 18.63% 6.66% 0.36x Within
2021-11-12 Pre-Market 1.09% 4.67% 4.28x Exceeded
2022-03-10 Pre-Market 13.85% 27.50% 1.99x Exceeded
2022-05-16 Pre-Market 20.52% 2.28% 0.11x Within
2022-08-15 Pre-Market 17.70% 0.33% 0.02x Within
2022-11-14 Pre-Market 9.31% 7.45% 0.80x Within
2023-11-14 Pre-Market 71.96% 0.25% 0.00x Within
2024-08-12 Pre-Market 336.71% 3.47% 0.01x Within
2024-11-12 Pre-Market 29.61% 1.32% 0.04x Within
2025-03-27 Pre-Market 47.03% 3.96% 0.08x Within
2025-05-13 Pre-Market 37.16% 2.70% 0.07x Within
2025-08-12 Pre-Market 212.96% 2.31% 0.01x Within
2025-11-13 Pre-Market 81.85% 3.57% 0.04x Within
2026-05-12 Pre-Market 441.33% 0.51% 0.00x Within
2026-08-11 Pre-Market 125.60% 0.00% 0.00x Within

Earnings calendar: this week’s reports with expected vs actual moves →

TXMD Options Activity & IV Rank

TXMD IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 117.1%
7-DTE IV: —
Expected Move: $0.72
7-DTE Move: $0.72
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 23
Put Volume: 2
P/C Volume: 0.087
BULLISH
Call OI: 54
Put OI: 1
P/C OI: 0.019
Total OI: 55

ATM Options Pricing

ATM Call: $0.38
ATM Put: $0.35
Call %: 20.8%
Put %: 19.4%

Chain Summary

Chain Volume: 271
Chain OI: 843
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Not enough history yet to rank today's net dealer gamma against this name's own record.

Gamma percentile
—
vs own history
GEX tilt
+1.00
OI-weighted, today
Vanna tilt
+1.00
δ-sensitivity to IV
Charm tilt
-0.98
δ-decay vs time
Vanna tilt +1.00: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.98: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 3 ATM contracts, 0k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 164.0% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)5.3LowOct 26
Straddle Price (30 DTE)$0.72Oct 26
Beta Analysis

Risk Metrics

Beta: 0.2111
Alpha: 56.95%
Correlation: 0.0368
R-Squared: 0.1%
Stock Volatility: 73.2%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own TXMD
2 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Renaissance Technologies Hedge fund
Jim Simons
$324K
0.00%
#2749 of 3138+0.3%13F
Citadel Hedge fund
Ken Griffin
$190K
0.00%
#5519 of 6285+26.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

TXMD Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 11,589,250 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

48 filers4,063,555 shares$8.75M value35.06% of float
# Filer Shares Value % of Total % of Float Period
1 Rubric Capital Management LP 1,192,191 $2.63M 30.11% 10.29% 2026-06-30
2 Clearline Capital LP 635,222 $1.40M 16.04% 5.48% 2026-06-30
3 Vanguard Capital Management LLC 353,697 $781.67K 8.93% 3.05% 2026-06-30
4 Tejara Capital Ltd 344,482 $761.30K 8.70% 2.97% 2026-06-30
5 ADAR1 Capital Management, LLC 342,447 $756.81K 8.65% 2.95% 2026-06-30
6 Vanguard Group Inc Custodian 397,056 $647.20K 7.40% 3.43% 2025-12-31
7 RENAISSANCE TECHNOLOGIES LLC 146,599 $323.98K 3.70% 1.26% 2026-06-30
8 Morgan Stanley Custodian 129,217 $285.57K 3.26% 1.11% 2026-06-30
9 BlackRock, Inc. Custodian 115,145 $254.47K 2.91% 0.99% 2026-06-30
10 Geode Capital Management, LLC Custodian 105,849 $233.99K 2.67% 0.91% 2026-06-30
11 Citadel Advisors LLC Custodian 86,095 $190.27K 2.17% 0.74% 2026-06-30
12 Vanguard Fiduciary Trust Co 63,831 $141.07K 1.61% 0.55% 2026-06-30
13 State Street Corp 30,100 $66.52K 0.76% 0.26% 2026-06-30
14 XTX Topco Ltd 21,246 $46.95K 0.54% 0.18% 2026-06-30
15 Dimensional Fund Advisors LP Custodian 19,719 $43.58K 0.50% 0.17% 2026-06-30
16 Northern Trust Corp Custodian 18,556 $41.01K 0.47% 0.16% 2026-06-30
17 BRIDGEWAY CAPITAL MANAGEMENT, LLC 17,000 $37.57K 0.43% 0.15% 2026-06-30
18 OSAIC HOLDINGS, INC. Custodian 15,198 $33.59K 0.38% 0.13% 2026-06-30
19 HRT FINANCIAL LP 14,727 $32.00K 0.37% 0.13% 2026-06-30
20 Vanguard Global Advisers, LLC 4,937 $10.91K 0.12% 0.04% 2026-06-30
21 UBS Group AG Custodian 4,660 $10.30K 0.12% 0.04% 2026-06-30
22 Tower Research Capital LLC (TRC) Custodian 1,582 $3.50K 0.04% 0.01% 2026-06-30
23 SBI Securities Co., Ltd. 1,263 $2.56K 0.03% 0.01% 2026-09-30
24 Smartleaf Asset Management LLC 601 $1.35K 0.02% <0.01% 2026-06-30
25 Royal Bank of Canada Custodian 833 $1.00K 0.01% <0.01% 2026-06-30
3 filers$85.75K notional
# Filer Notional Value % of Total Period
1 Simplex Trading, LLC Custodian $29.17K 34.02% 2026-06-30
2 Susquehanna International Group, LLP Custodian $28.95K 33.76% 2026-06-30
3 Jane Street Group, LLC Custodian $27.62K 32.22% 2026-06-30
# Filer Notional Value % of Total Period

TXMD Insider Trading (Form 4)

Latest: 2025-12-29
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2025-12-29 Tommy G Thompson Director Buy (P) +8,400 $1.67 $14.0K EDGAR
2025-11-05 Marlan D Walker Chief Executive Officer Grant (A) +67,492 opt — EDGAR
2025-11-05 Gail K Naughton Director Grant (A) +8,500 RSU — EDGAR
2025-11-05 Cooper C. Collins Director Grant (A) +8,500 RSU — EDGAR
2025-11-05 Tommy G Thompson Director Grant (A) +8,500 RSU — EDGAR
2025-04-15 Tommy G Thompson Director Buy (P) +325 $1.00 $326 EDGAR
2025-04-15 Marlan D Walker Chief Executive Officer Buy (P) +490 $1.00 $489 EDGAR
2025-04-10 Marlan D Walker Chief Executive Officer Buy (P) +2,303 $0.87 $2.0K EDGAR
2025-02-20 Marlan D Walker Chief Executive Officer Exer (M) +8,281 — EDGAR
2025-02-20 Tommy G Thompson Director Exer (M) +8,500 — EDGAR
2025-02-20 Cooper C. Collins Director Exer (M) +8,500 — EDGAR
2025-02-20 Gail K Naughton Director Exer (M) +8,500 — EDGAR
2024-08-26 Cooper C. Collins Director Buy (P) +4,094 $1.73 $7.1K EDGAR
2024-08-23 Cooper C. Collins Director Buy (P) +1,200 $1.70 $2.0K EDGAR
2023-12-07 Marlan D Walker Chief Executive Officer Mixed +50,950 $2.29 -$43.7K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

TXMD Insider Holdings

4 insiders · @ $1.80
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Marlan D Walker Chief Executive Officer 73,639 $132.6K -$75.6K 16 2025-11-05
2 Cooper C. Collins Director 60,516 $108.9K -$2.99M 24 2025-11-05
3 Tommy G Thompson Director 37,491 $67.5K $310.4K 31 2025-12-29
4 Gail K Naughton Director 8,500 $15.3K -$20.6K 9 2025-11-05
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

TXMD Board & Officers

As of SEC filings through Dec 29, 2025

Directors 4

Officers 1

Changes in the last 10 years (38)
Aug 17, 2023Joseph Ziegler became Principal Financial Officer
Jun 29, 2023Rubric Capital Management LP reported in an SEC filing no longer being a director
Jun 29, 2023Rubric Capital Management LP reported in an SEC filing no longer being a 10% owner
Jun 29, 2023David Efraim Rosen reported in an SEC filing no longer being a director
Jun 29, 2023David Efraim Rosen reported in an SEC filing no longer being a 10% owner
Feb 22, 2023Rubric Capital Management LP first listed as a director in an SEC filing
Feb 22, 2023David Efraim Rosen first listed as a director in an SEC filing
Feb 21, 2023The company announced the departure of Michael C Donegan as Prin. Fin. and Acctg. Officer in an SEC filing
Feb 13, 2023Marlan D Walker listed as Chief Executive Officer (previously General Counsel) in SEC filings
Jan 25, 2023Michael C Donegan listed as Prin. Fin. and Acctg. Officer (previously CAO and VP of Finance) in SEC filings
Dec 30, 2022The company announced the departure of Paul Bisaro from the board in an SEC filing
Dec 30, 2022The company announced the departure of Karen Ling from the board in an SEC filing
Dec 30, 2022The company announced the departure of Jules A. Musing from the board in an SEC filing
Dec 30, 2022The company announced the departure of Angus C. Russell from the board in an SEC filing
Sep 16, 2022Brian Bernick no longer listed as a director in SEC filings
Sep 16, 2022Brian Bernick first listed as Co-Chief Executive Officer in an SEC filing
Aug 23, 2022Justin Hunter Roberts became a director
Jul 14, 2022Rubric Capital Management LP became a 10% owner
Jul 14, 2022David Efraim Rosen became a 10% owner
Mar 28, 2022Hugh O'Dowd listed as Chief Executive Officer (previously President) in SEC filings
Not reported recently (12)
  • Joseph Ziegler · Last reported as Principal Financial Officer in an SEC filing dated Aug 21, 2023
  • Brian Bernick · Last reported as Co-Chief Executive Officer in an SEC filing dated Dec 9, 2022
  • Mark A Glickman · Last reported as Chief Business Officer in an SEC filing dated Dec 9, 2022
  • Hugh O'Dowd · Last reported as Chief Executive Officer in an SEC filing dated Mar 31, 2022
  • James DArecca · Last reported as Chief Financial Officer in an SEC filing dated Aug 12, 2021
  • Edward Borkowski · Last reported as EVP, Operations in an SEC filing dated Jul 2, 2021
  • John C.K. Milligan IV · Last reported as President/Secretary in an SEC filing dated May 12, 2021
  • Mitchell Krassan · Last reported as Chief Strategy Officer in an SEC filing dated Apr 1, 2020
  • Daniel A Cartwright · Last reported as Chief Financial Officer in an SEC filing dated Apr 1, 2020
  • Jane F Barlow · Last reported as a director in an SEC filing dated Aug 14, 2019
  • Nicholas Segal · Last reported as a director in an SEC filing dated Jun 24, 2019
  • Robert V LaPenta Jr · Last reported as a director in an SEC filing dated Jun 24, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

TXMD Proposed Insider Sales (Form 144)

Latest: 2023-12-06
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2023-12-06 Walker Marlan D Officer 28,134 $70.1K 2023-12-06 RAYMOND JAMES & ASSOCIATES INC — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
6 ETFs hold TXMD
6 shown · $830.46K total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $495,964 — 2026-09-30
2 VXF Vanguard Extended Market ETF Vanguard 0.00% $304,662 — 2026-09-30
3 DXUV Dimensional US Vector Equity ETF Dimensional 0.00% $9,113 — 2026-10-23
4 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $8,687 — 2026-10-23
5 DFSU Dimensional US Sustainability Core 1 ETF Dimensional 0.00% $6,502 $2.4B 2026-10-23
6 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $5,537 — 2026-10-23
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
90.00
TTM Diluted EPS
$0.02
TTM Revenue
$3.35M
TTM Net Income
$179.00K
TTM Op. Cash Flow
$2.68M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31$724.00K$95.00K$0.01$944.00K
Q4 '252025-12-31$893.00K$-619.00K$-0.05$368.00K
Q3 '252025-09-30$784.00K$152.00K$0.01$1.05M
Q2 '252025-06-30$952.00K$551.00K$0.05$324.00K
Q1 '252025-03-31$393.00K$-653.00K$-0.06$699.00K
Q4 '242024-12-31$667.00K$252.00K$0.02$12.00K
Q3 '242024-09-30$547.00K$-609.00K$-0.05$-185.00K
Q2 '242024-06-30$234.00K$-1.09M$-0.09$894.00K
Q1 '242024-03-31$313.00K$-734.00K$-0.06$11.00K
Q4 '232023-12-31$502.00K$-883.00K$-0.07$-7.84M
Q3 '232023-09-30$-53.00K$-3.38M$-0.32$-2.46M
Q2 '232023-06-30$437.00K$-2.41M$-0.24$-4.67M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-12
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
90.00
P/B
0.77
P/S
6.22
EV/EBITDA
—
EV/Sales
3.71
ROE
0.7%
ROA
0.5%
Div Yield
0.00%
FCF Yield
12.86%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$20.86M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
23.66K
SI % of Float
0.24%
Days to Cover
1.39
Short Vol Ratio
62.2%
Free Float
10.05M
Float %
86.8%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14